Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
ImmunityBio ( (IBRX) ) just unveiled an update.
On April 6, 2026, ImmunityBio, Inc. announced it had submitted a comprehensive response to a March 13, 2026 Warning Letter from the U.S. FDA’s Office of Prescription Drug Promotion concerning a podcast and a television advertisement related to ANKTIVA. The company stated the television ad was never aired, removed the cited podcast from its own and third-party platforms, and initiated a broad review of promotional materials with legal and regulatory teams.
ImmunityBio outlined corrective and compliance measures including expanded promotional review protocols, mandatory executive training, and engagement of external regulatory counsel to oversee future high-visibility communications. The company also clarified that the statements cited in the podcast by Founder and Executive Chairman Dr. Patrick Soon-Shiong were intended as aspirational commentary on its IL-15-based oncology platform, seeking to reinforce its commitment to accurate, balanced promotion and to limit regulatory and reputational risk around its commercialization of ANKTIVA.
The most recent analyst rating on (IBRX) stock is a Hold with a $7.00 price target. To see the full list of analyst forecasts on ImmunityBio stock, see the IBRX Stock Forecast page.
Spark’s Take on IBRX Stock
According to Spark, TipRanks’ AI Analyst, IBRX is a Neutral.
The score is held back primarily by weak financial fundamentals (large ongoing losses, heavy cash burn, and negative equity). Earnings-call updates provide a meaningful offset via strong ANKTIVA commercialization and expanding regulatory approvals, but near-term technical signals are still bearish and valuation remains hard to justify without profitability.
To see Spark’s full report on IBRX stock, click here.
More about ImmunityBio
ImmunityBio, Inc. is a commercial-stage biotechnology company focused on developing and commercializing next-generation immunotherapies targeting cancer and infectious diseases. Its core Cancer BioShield platform leverages a proprietary IL-15 superagonist to activate natural killer cells, cytotoxic T cells, and memory T cells, anchored by the first-in-class IL-15 agonist fusion complex ANKTIVA for BCG-unresponsive non-muscle invasive bladder cancer.
The company’s portfolio includes approved ANKTIVA in combination with BCG, as well as an investigational pipeline of adenovirus-vectored vaccines, allogeneic and autologous NK-cell therapies, and other immunomodulators aimed at inducing durable immune responses while potentially reducing reliance on high-dose chemo-radiation therapies.
Average Trading Volume: 39,794,519
Technical Sentiment Signal: Strong Buy
Current Market Cap: $7.51B
See more data about IBRX stock on TipRanks’ Stock Analysis page.